Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
Globe Newswire•27/08/2026•08:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.